| Name | Title | Contact Details |
|---|
Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent target protein degraders that address the limitations of heterobifunctional degraders and cereblon IMiDs. The company is powered by its proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases. Due to its expertise in TPD, Plexium has entered into strategic collaborations with Amgen and AbbVie to discover and develop a wide range of new therapies from cancer to neurological diseases. Supported by high quality investors, Plexium is well positioned to transform medicine.
Advanced Enzyme Technologies Limited is engaged in business of manufacturing and sale of enzymes. The Companys geographical segments include Within India and Outside India. It provides solutions to industries, such as human healthcare and nutrition, a...
Kymanox is a professional services organization with a focus on project delivery. Our team of experts provide guide you and your project.
eNeura Therapeutics is a Medical Device company located in 240 N. Wolfe Rd., Sunnyvale, CA, United States.
BreakBio Corp is a biotechnology company focused on breakthrough cancer treatment and prevention. They use their proprietary AI platform to find multiple proteins on each patients cancer cells and custom manufacture drugs for each patient. Their goal ...